Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Versor Investments LP

Versor Investments LP increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 12.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,873 shares of the company’s stock after acquiring an additional 442 shares during the period. Versor Investments LP’s holdings in Medpace were worth $1,595,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Rise Advisors LLC purchased a new position in shares of Medpace in the 1st quarter valued at about $27,000. Mather Group LLC. acquired a new position in shares of Medpace during the 1st quarter worth approximately $28,000. GAMMA Investing LLC acquired a new stake in Medpace in the 4th quarter valued at $30,000. Fidelis Capital Partners LLC purchased a new position in Medpace in the 1st quarter valued at about $31,000. Finally, J.Safra Asset Management Corp boosted its holdings in Medpace by 87.0% in the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after buying an additional 47 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Performance

Shares of MEDP traded down $10.67 during mid-day trading on Monday, hitting $355.27. 655,700 shares of the company’s stock were exchanged, compared to its average volume of 246,022. The stock’s 50-day moving average is $397.14 and its 200-day moving average is $396.95. Medpace Holdings, Inc. has a fifty-two week low of $227.21 and a fifty-two week high of $459.77. The company has a market cap of $11.01 billion, a price-to-earnings ratio of 36.22, a P/E/G ratio of 1.85 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, July 22nd. The company reported $2.75 EPS for the quarter, beating the consensus estimate of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The company had revenue of $528.10 million during the quarter, compared to analysts’ expectations of $528.41 million. During the same quarter last year, the company posted $1.93 EPS. The firm’s revenue was up 14.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 11.66 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on MEDP shares. StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a research note on Friday, August 9th. TD Cowen reduced their target price on shares of Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a research report on Wednesday, July 24th. William Blair restated an “outperform” rating on shares of Medpace in a research report on Tuesday, July 23rd. Deutsche Bank Aktiengesellschaft lowered their price objective on Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research note on Wednesday, July 24th. Finally, Truist Financial began coverage on shares of Medpace in a research report on Thursday, August 1st. They set a “hold” rating and a $415.00 price target on the stock. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $423.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.